KLRK1 and cancer: With ongoing clinical advancements, the integration of NKG2D and its signaling adaptors into adoptive T cell therapies holds promise for improving patient outcomes in cancer and beyond, reinforcing the potential of harnessing innate-like signaling pathways in adaptive immune responses.